PHARMACYTE BIOTECH, INC. (PMCB) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-07-31..
Quick ratio
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 768.68K USD | Liabilities, Current |
| Cash and equivalents | 17.74M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 99.46K USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | (m) | $768.68K | $17.74M | $99.46K | (m) | (m) | (m) |
| 2026-04-30 | (m) | $826.42K | $18.60M | $254.01K | (m) | (m) | (m) |
| 2026-01-31 | (m) | $1.68M | $20.17M | $372.25K | (m) | (m) | (m) |
| 2025-10-31 | (m) | $1.58M | $15.41M | $201.19K | (m) | (m) | (m) |
| 2025-07-31 | (m) | $1.06M | $13.18M | $261.85K | (m) | (m) | (m) |
| 2025-04-30 | (m) | $2.91M | $15.17M | $366.32K | (m) | (m) | (m) |
| 2025-01-31 | (m) | $1.19M | $16.38M | $372.63K | (m) | (m) | (m) |
| 2024-10-31 | (m) | $4.78M | $20.84M | (m) | (m) | (m) | (m) |
| 2024-07-31 | (m) | $7.47M | $32.64M | (m) | (m) | (m) | (m) |
| 2024-04-30 | (m) | $7.42M | $50.18M | (m) | (m) | (m) | (m) |
| 2024-01-31 | (m) | $7.54M | $61.21M | (m) | (m) | (m) | (m) |
| 2023-10-31 | (m) | $5.24M | $73.43M | (m) | (m) | (m) | (m) |
| 2023-07-31 | (m) | $1.52M | $74.66M | (m) | (m) | (m) | (m) |
| 2023-04-30 | (m) | $586.58K | $68.04M | (m) | (m) | (m) | (m) |
| 2023-01-31 | (m) | $827.83K | (m) | (m) | (m) | (m) | (m) |
| 2022-10-31 | (m) | $1.31M | (m) | (m) | (m) | (m) | (m) |
| 2022-07-31 | (m) | $1.09M | (m) | (m) | (m) | (m) | (m) |
| 2022-04-30 | (m) | $704.37K | (m) | (m) | (m) | (m) | (m) |
| 2022-01-31 | (m) | $612.98K | (m) | (m) | (m) | (m) | (m) |
| 2021-10-31 | (m) | $186.12K | (m) | (m) | (m) | (m) | (m) |
| 2021-07-31 | (m) | $924.97K | (m) | (m) | (m) | (m) | (m) |
| 2021-04-30 | (m) | $724.78K | (m) | (m) | (m) | (m) | (m) |
| 2021-01-31 | (m) | $640.25K | (m) | (m) | (m) | (m) | (m) |
| 2020-10-31 | (m) | $643.65K | (m) | (m) | (m) | (m) | (m) |
| 2020-07-31 | (m) | $1.15M | (m) | (m) | (m) | (m) | (m) |
| 2020-04-30 | (m) | $1.03M | (m) | (m) | (m) | (m) | (m) |
| 2020-01-31 | (m) | $1.02M | (m) | (m) | (m) | (m) | (m) |
| 2019-10-31 | (m) | $803.86K | (m) | (m) | (m) | (m) | (m) |
| 2019-07-31 | (m) | $606.56K | (m) | (m) | (m) | (m) | (m) |
| 2019-04-30 | (m) | $742.85K | (m) | (m) | (m) | (m) | (m) |
| 2019-01-31 | (m) | $471.24K | (m) | (m) | (m) | (m) | (m) |
| 2018-10-31 | (m) | $662.37K | (m) | (m) | (m) | (m) | (m) |
| 2018-07-31 | (m) | $882.94K | (m) | (m) | (m) | (m) | (m) |
| 2018-04-30 | (m) | $644.17K | (m) | (m) | (m) | (m) | (m) |
| 2018-01-31 | (m) | $887.16K | (m) | (m) | (m) | (m) | (m) |
| 2017-10-31 | (m) | $566.96K | (m) | (m) | (m) | (m) | (m) |
| 2017-07-31 | (m) | $865.68K | (m) | (m) | (m) | (m) | (m) |
| 2017-04-30 | (m) | $580.25K | (m) | (m) | (m) | (m) | (m) |
| 2017-01-31 | (m) | $578.27K | (m) | (m) | (m) | (m) | (m) |
| 2016-10-31 | (m) | $448.99K | (m) | (m) | (m) | (m) | (m) |
| 2016-07-31 | (m) | $456.46K | (m) | (m) | (m) | (m) | (m) |
| 2016-04-30 | (m) | $637.64K | (m) | (m) | (m) | (m) | (m) |
| 2016-01-31 | (m) | $1.07M | (m) | (m) | (m) | (m) | (m) |
| 2015-10-31 | (m) | $1.08M | (m) | (m) | (m) | (m) | (m) |
| 2015-07-31 | (m) | $1.19M | (m) | (m) | (m) | (m) | (m) |
| 2015-04-30 | (m) | $2.01M | (m) | (m) | (m) | (m) | (m) |
| 2015-01-31 | (m) | $378.51K | $958.82K | (m) | (m) | (m) | (m) |
| 2014-10-31 | (m) | $276.86K | $1.16M | (m) | (m) | (m) | (m) |
| 2014-07-31 | (m) | $371.39K | (m) | (m) | (m) | (m) | (m) |
| 2014-04-30 | (m) | $373.67K | (m) | (m) | (m) | (m) | (m) |
| 2014-01-31 | (m) | $479.28K | (m) | (m) | (m) | (m) | (m) |
| 2013-10-31 | (m) | $990.97K | (m) | (m) | (m) | (m) | (m) |
| 2013-07-31 | (m) | $994.15K | $206.04K | (m) | (m) | (m) | (m) |
| 2013-04-30 | (m) | $3.80M | $199.30K | (m) | (m) | $0.00 | (m) |
| 2013-01-31 | (m) | $3.61M | $33.33K | (m) | (m) | $0.00 | (m) |
| 2012-10-31 | (m) | $3.50M | $22.70K | (m) | (m) | $0.00 | (m) |
| 2012-07-31 | (m) | $4.03M | $24.34K | (m) | (m) | $9.62K | (m) |
| 2012-04-30 | (m) | $3.79M | $15.72K | (m) | $2.58K | $6.85K | (m) |
| 2012-01-31 | (m) | $3.28M | $39.08K | (m) | (m) | $2.31K | (m) |
| 2011-10-31 | (m) | $3.52M | $14.51K | (m) | (m) | $4.52K | (m) |
| 2011-07-31 | (m) | $3.40M | $83.07K | (m) | (m) | $7.62K | (m) |
| 2011-04-30 | (m) | $3.39M | $57.20K | (m) | (m) | $18.71K | (m) |
| 2011-01-31 | (m) | (m) | $3.61K | (m) | (m) | (m) | (m) |
| 2010-10-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2010-07-31 | (m) | (m) | $547.00 | (m) | (m) | (m) | (m) |
| 2010-04-30 | (m) | (m) | $716.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |